See more : Broadstone Net Lease, Inc. (BNL) Income Statement Analysis – Financial Results
Complete financial analysis of Kinnate Biopharma Inc. (KNTE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Kinnate Biopharma Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Deutsche Börse AG (DBOEY) Income Statement Analysis – Financial Results
- illimity Bank S.p.A. (ILTY.MI) Income Statement Analysis – Financial Results
- Firstsource Solutions Limited (FSL.BO) Income Statement Analysis – Financial Results
- Chongqing Qin’an M&E PLC. (603758.SS) Income Statement Analysis – Financial Results
- Ningbo Shenglong Automotive Powertrain System Co.,Ltd. (603178.SS) Income Statement Analysis – Financial Results
Kinnate Biopharma Inc. (KNTE)
About Kinnate Biopharma Inc.
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 799.00K | 604.00K | 123.00K | 83.00K | 0.00 | 0.00 |
| Gross Profit | -799.00K | -604.00K | -123.00K | -83.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 90.77M | 88.15M | 67.17M | 29.24M | 8.96M | 5.68M |
| General & Administrative | 0.00 | 30.37M | 22.95M | 6.76M | 3.06M | 1.96M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 27.44M | 30.37M | 22.95M | 6.76M | 3.06M | 1.96M |
| Other Expenses | 0.00 | 2.25M | 348.00K | -5.00K | 0.00 | 0.00 |
| Operating Expenses | 118.21M | 118.52M | 90.11M | 36.00M | 12.01M | 7.63M |
| Cost & Expenses | 119.01M | 118.52M | 90.11M | 36.00M | 12.01M | 7.63M |
| Interest Income | 8.53M | 0.00 | 348.00K | 245.00K | 43.00K | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 799.00K | 604.00K | 123.00K | 83.00K | 171.86K | 161.14K |
| EBITDA | -118.21M | -117.92M | -89.99M | -35.92M | -12.01M | -7.63M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -119.01M | -118.52M | -90.11M | -36.00M | -12.01M | -7.63M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 6.36M | 2.25M | 348.00K | 240.00K | 43.00K | 0.00 |
| Income Before Tax | -112.65M | -116.27M | -89.76M | -35.76M | -11.97M | -7.63M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -2.25M | -348.00K | -328.00K | -43.00K | 0.00 |
| Net Income | -112.65M | -114.02M | -89.42M | -35.43M | -11.93M | -7.63M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.42 | -2.59 | -2.05 | -0.81 | -0.28 | -0.71 |
| EPS Diluted | -2.42 | -2.59 | -2.05 | -0.81 | -0.28 | -0.71 |
| Weighted Avg Shares Out | 46.58M | 44.07M | 43.60M | 43.48M | 43.33M | 10.80M |
| Weighted Avg Shares Out (Dil) | 46.58M | 44.07M | 43.60M | 43.48M | 43.33M | 10.80M |
KINNATE BIOPHARMA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTE
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Kinnate Biopharma Inc. (NasdaqGS: KNTE) to XOMA Corporation (NasdaqGM: XOMA). Under...
Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre Laboratories
Kinnate has entered into an Asset Purchase Agreement (the "APA") with Pierre Fabre Laboratories for global rights to exarafenib and other pan-RAF program assets. The transaction is in furtherance of Kinnate's previously announced pursuit of strategic alternatives.
Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre Laboratories
SAN FRANCISCO, SAN DIEGO and CASTRES, France, March 01, 2024 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate” or the “Company”), a clinical-stage precision oncology company, and Pierre Fabre Médicament, SAS (“Pierre Fabre Laboratories”), a global player in oncology,...
Kinnate Biopharma Inc. (KNTE) Upgraded to Buy: What Does It Mean for the Stock?
Kinnate Biopharma Inc. (KNTE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
KINNATE BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTE
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Kinnate Biopharma Inc. (NasdaqGS: KNTE) to XOMA Corporation (NasdaqGM: XOMA). Under...
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Kinnate Biopharma Inc.
NEW YORK , Feb. 16, 2024 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Kinnate Biopharma Inc. (NASDAQ: KNTE) and its board of directors concerning the proposed acquisition of the company by XOMA Corporation. Stockholders will...
Shareholder Alert: Ademi LLP investigates whether Kinnate Biopharma Inc. has obtained a Fair Price in its transaction with XOMA
MILWAUKEE , Feb. 16, 2024 /PRNewswire/ -- Ademi LLP is investigating Kinnate (Nasdaq: KNTE) for possible breaches of fiduciary duty and other violations of law in its transaction with XOMA. Click here to learn how to join the https://www.ademilaw.com/case/kinnate-biopharma-inc or...
KNTE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Kinnate Biopharma Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Kinnate Biopharma Inc. (NASDAQ: KNTE) to XOMA Corporation is fair to Kinnate shareholders. Under the terms of the proposed transaction, XOMA would acquire Kinnate...
Kinnate Biopharma Inc. Enters into Agreement to be Acquired by XOMA Corporation for Between $2.3352 and $2.5879 Per Share in Cash, Plus One Contingent Value Right per Share
SAN FRANCISCO and SAN DIEGO, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate” or the “Company”), a clinical-stage precision oncology company, today announced it has entered into a definitive merger agreement (the "Merger Agreement") whereby XOMA...
Kinnate Biopharma Inc. Reports Third Quarter 2023 Financial Results and Recent Corporate Updates
SAN FRANCISCO and SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc . (Nasdaq: KNTE) (“Kinnate” or the “Company”), a clinical-stage precision oncology company, today announced financial results for the third quarter of 2023 and recent corporate updates.
Source: https://incomestatements.info
Category: Stock Reports